➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Merck
Moodys
McKinsey

Last Updated: April 11, 2021

DrugPatentWatch Database Preview

Benoxinate hydrochloride; fluorescein sodium - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for benoxinate hydrochloride; fluorescein sodium and what is the scope of patent protection?

Benoxinate hydrochloride; fluorescein sodium is the generic ingredient in two branded drugs marketed by Altaire Pharms Inc and Bausch, and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Benoxinate hydrochloride; fluorescein sodium has four patent family members in four countries.

There is one drug master file entry for benoxinate hydrochloride; fluorescein sodium. Three suppliers are listed for this compound.

Summary for benoxinate hydrochloride; fluorescein sodium
International Patents:4
US Patents:3
Tradenames:2
Applicants:2
NDAs:2
Drug Master File Entries: 1
Suppliers / Packagers: 3
Clinical Trials: 1
DailyMed Link:benoxinate hydrochloride; fluorescein sodium at DailyMed
Recent Clinical Trials for benoxinate hydrochloride; fluorescein sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Centre de recherche du Centre hospitalier universitaire de SherbrookeN/A

See all benoxinate hydrochloride; fluorescein sodium clinical trials

Pharmacology for benoxinate hydrochloride; fluorescein sodium
Drug ClassDiagnostic Dye
Mechanism of ActionDyes

US Patents and Regulatory Information for benoxinate hydrochloride; fluorescein sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Altaire Pharms Inc ALTAFLUOR BENOX benoxinate hydrochloride; fluorescein sodium SOLUTION/DROPS;OPHTHALMIC 208582-001 Dec 14, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bausch FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE benoxinate hydrochloride; fluorescein sodium SOLUTION/DROPS;OPHTHALMIC 211039-001 Mar 9, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Bausch FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE benoxinate hydrochloride; fluorescein sodium SOLUTION/DROPS;OPHTHALMIC 211039-001 Mar 9, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Bausch FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE benoxinate hydrochloride; fluorescein sodium SOLUTION/DROPS;OPHTHALMIC 211039-001 Mar 9, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Johnson and Johnson
AstraZeneca
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.